Human papillomavirus-related oropharyngeal carcinoma
Human papillomavirus-related oropharyngeal carcinoma
复制标题
人乳头瘤病毒相关口咽癌
DOI：
10.1093/jjco/hyac049
复制
发表时间：
2022
影响因子：
2.4
通讯作者：
Imamura Yoshinori
中科院分区：
文献类型：
--
作者：
Saito Yuki;Homma Akihiro;Kiyota Naomi;Tahara Makoto;Hanai Nobuhiro;Asakage Takahiro;Matsuura Kazuto;Ota Ichiro;Yokota Tomoya;Sano Daisuke;Kodaira Takeshi;Motegi Atsushi;Yasuda Koichi;Takahashi Shunji;Tanaka Kaoru;Onoe Takuma;Okano Susumu;Imamura Yoshinori
直到2000年左右，人乳头瘤病毒相关的口咽癌才被认为是一种临床表现不同于非相关头颈部癌的癌症。20年后，随着2017年肿瘤淋巴结转移分类的修订，各种临床试验都集中在人乳头瘤病毒相关的口咽癌上，以改善这种疾病患者的预后和生活质量。然而，人乳头瘤病毒相关癌症的发病率正在增加，预计这在日本尤为突出，因为日本人乳头瘤病毒疫苗接种并不普遍。在这篇综述中，我们描述了日本人乳头瘤病毒相关口咽癌的一级和二级预防的临床试验（主要集中在初次手术和减少辐射剂量）的现状。
It was not until around 2000 that human papillomavirus-related oropharyngeal carcinoma was recognized as carcinoma with clinical presentations different from nonrelated head and neck carcinoma. Twenty years after and with the revision of the tumor–node–metastasis classification in 2017, various clinical trials focused on human papillomavirus-related oropharyngeal carcinoma to improve the prognosis and quality of life of patients with this disease. However, the incidence of human papillomavirus-related cancers is increasing, which is expected to be particularly prominent in Japan, where human papillomavirus vaccination is not widely available. In this review, we describe the current status of clinical trials (mainly focused on initial surgery and radiation dose reduction) for, primary and secondary prevention of, and the present status of human papillomavirus-related oropharyngeal carcinoma in Japan.